Download the White Paper
Biomarkers play an increasingly important role when it comes to reimbursement decisions for new therapies based on cost-effectiveness. A high number of approved drugs currently in the market have a patient benefit ratio of 25%, at best, to an appalling low ratio of 4%. Interestingly and unexpectedly, the target indications for the drugs listed within this white paper have all been recently linked to dysbiosis in the microbiome.
Learn more. Complete and submit the form below and receive an email containing a link to access and save the whitepaper:
This paper provides an introduction to microbiome-based biomarkers and the use of microbiome data as one component of a larger data profile for individuals in today’s era of precision medicine:
- The application of biomarkers enabling “targeted therapies” or serving as surrogate efficacy markers to shorten otherwise lengthy clinical trials.
- How microbiome information may be used for risk prediction, diagnosis and progression of disease and for stratification of subjects in clinical drug trials.
- The role biomarkers play in reimbursement decisions for new therapies based on cost-effectiveness.
- An example process for biomarker identification and validation.
- How a customized approach, sequencing depth, and delivery of high quality data are able to infer metabolic potential for more targeted hypothesis generation.
Please fill out the form below: